Premium
THE ANGIOTENSIN‐CONVERTING ENZYME INHIBITOR, PERINDOPRIL, PREVENTS CARDIAC HYPERTROPHY IN LOW‐RENIN HYPERTENSIVE RATS
Author(s) -
Nakamura Fumiaki,
Nagano Masahiro,
Higaki Jitsuo,
Higashimori Koichi,
Morishita Ryuichi,
Mikami Hiroshi,
Ogihara Toshio
Publication year - 1993
Publication title -
clinical and experimental pharmacology and physiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.752
H-Index - 103
eISSN - 1440-1681
pISSN - 0305-1870
DOI - 10.1111/j.1440-1681.1993.tb01660.x
Subject(s) - perindopril , cardiac hypertrophy , renin–angiotensin system , angiotensin converting enzyme , medicine , endocrinology , muscle hypertrophy , pharmacology , cardiology , blood pressure
SUMMARY 1. To examine whether an angiotensin‐converting enzyme (ACE) inhibitor prevents left ventricular (LV) hypertrophy even in low‐renin hypertension, we studied the effect of the administration of perindopril on cardiac hypertrophy induced by partial renal ablation in hypertensive rats. 2. Rats that had undergone partial nephrectomy were randomly divided into four groups that received the following as drinking water: Group A, tap water; Group B, 1% sodium chloride (NaCl); Group C, NaCl + perindopril 3 mg/ kg per day; and Group D, NaCl + perindopril 1 mg/ kg per day. Plasma renin activity (PRA), angiotensin‐II (AII) concentration and cardiac tissue AII were measured. 3. Supplementation of NaCl following nephrectomy increased the blood pressure and cardiac weight compared with rats that had undergone nephrectomy alone ( P <0.05). Treatment with perindopril (3 mg/kg per day) did not affect the blood pressure and plasma AII but inhibited the increase of cardiac weight ( P <0.05). Left ventricular AII was decreased in cases of reduced renal mass hypertension, but was not changed by treatment with perindopril. 4. These results demonstrate that perindopril may be able to prevent LV hypertrophy even in low‐renin hypertension, which was not mediated by a reduction of blood pressure or suppression of the circulating and cardiac renin‐angiotensin systems. Other mechanisms of ACE inhibitors may contribute to the cardioprotective effects.